Markers useful for separating Paget disease from other processes. CK7 is the most useful marker as it is not expressed by the surrounding epidermal cells.SurgicalPathologyCriteriahttp://surgpathcriteria.stanford.edu/usebrowserbackbuttontoreturnExtramammaryPagetDiseaseDefinitionIntraepithelialinvolvementoftheskinby(non-squamous)carcinomacellsDiagnosticCriteriaIntraepithelialpopulationoflargeatypicalcells(Pagetcells)distinctfromsurroundingnormalepithelialcellsLargenuclei,prominentnucleoliAbundantpalecytoplasmScatteredindividuallyandinclustersMayformsmallaciniLackfeaturesofsquamousdifferentiationNovisibleintercellularbridgesNotransitiontosurroundingsquamouscellsMostcasesmucinpositiveMayformsignetringsUnderlyingchronicinflammationcommonEpidermalhyperplasiaandhyperkeratosisandparakeratosisfrequentlypresentPresentinhalfofcases>90%ofanalcasesThreepatternsdescribedSquamoushyperplasiaNOSMayresultinpseudoepitheliomatoushyperplasiaFibroepithelioma-likeAnastomosingnetworkofreteridgesEspeciallyfrequentinperianalcasesPapillomatousHPVnegativePagetcellsmaybeshrunkenandpyknoticExtramammaryPagetdiseasecanbeseparatedintoprimaryandsecondarytypesPrimarytypenotassociatedwithunderlyingdeepcarcinomaPositiveforGCDFP15andnegativeforCK20(seeSupplementalStudiesandDifferentialDiagnosisatleftsidebar)Invasionisuncommon,butcanoccurSecondarytypeisassociatedwithanunderlyinginternalcarcinomaNegativeforGCDFP15andfrequentlyCK20positivePhenotypemaydependuponnatureofunderlyingcarcinomaMostcommonunderlyingcarcinomasRectaladenocarcinomaUrothelial(transitionalcell)carcinomaMostcommonlocationsVulvaAnal/perianalScrotumandpenisInguinalTeriALongacreMDRobertVRouseMDDepartmentofPathologyStanfordUniversitySchoolofMedicineStanfordCA94305-5342Originalposting/updates:10/7/10SupplementalstudiesImmunohistologyMarkersusefulforseparatingPagetdiseasefromotherprocessesCK7isthemostusefulmarkerasitisnotexpressedbythesurroundingepidermalcellsNormalTokercellsandMerkelcellsarepositiveforCK7andmustbedistinguishedmorphologicallyC

Forty percent of infiltrative basal cell carcinoma expressed CK7; while ... Archival materials were retrieved from the pathology files of UMass ...SkiptomaincontentThankyouforvisitingnature.com.YouareusingabrowserversionwithlimitedsupportforCSS.Toobtainthebestexperience,werecommendyouuseamoreuptodatebrowser(orturnoffcompatibilitymodeinInternetExplorer).Inthemeantime,toensurecontinuedsupport,wearedisplayingthesitewithoutstylesandJavaScript.AdvertisementnaturemodernpathologyoriginalarticlearticleMicrocysticadnexalcarcinoma:animmunohistochemicalreappraisalDownloadPDFAbstractEventhoughimmunohistochemicalcomparisonsofmicrocysticadnexalcarcinomavsinfiltrativebasalcellcarcinomaanddesmoplastictrichoepitheliomaexist,theyaremostlyrestrictedtotheuseofasinglestain.Inaddition,acomparisonwithsquamouscellcarcinomahasnotbeenreportedpreviously.Inthisstudy,wecomparetheexpressionofcytokeratin(CK)15,CK7,CK20,CK903,carcinoembryonicantigen(CEA),CD10,CD15andBerEP4in13microcysticadnexalcarcinoma,eightdesmoplastictrichoepithelioma,10infiltrativebasalcellcarcinoma,andeightsquamouscellcarcinomaofwhichfiveexhibitedductaldifferentiation.Wefoundthatthemajorityofmicrocysticadnexalcarcinoma(92%)anddesmoplastictrichoepithelioma(100%)casesexpressedCK15whiletheinfiltrativebasalcellcarcinomaandsquamouscellcarcinomacaseswereallnegative.FortypercentofinfiltrativebasalcellcarcinomaexpressedCK7;whileonlytwomicrocysticadnexalcarcinomacases(15%)andonesquamouscellcarcinomawithductaldifferentiation(12%)expressedCK7intheremainingthreetumorcategories.NoneofthedesmoplastictrichoepitheliomaexpressedCK7.AlltumorswerestronglypositiveforCK903.Whiletheneoplasticcellswerenegative,luminalstainingofductalstructureswasnotedforCK7,CD15andCEAinsomeofthemicrocysticadnexalcarcinoma,desmoplastictrichoepitheliomaandsquamouscellcarcinomawithductaldifferentiationcases.Sixtypercentofinfiltrativebasalcellcarcinoma,31%ofmicrocysticadnexalcarcinoma,and25%ofsquamouscellcarcinomaexpressCD10.BerEP4expressionwasnotedin38%ofmicrocysticad

CK7/CK20 staining pattern and CDX2 expression were evaluated in ... files of the Department of Pathology, Fatih University Medical School, ...SkiptomaincontentAdvertisementSearchallBMCarticlesSearchDownloadPDFResearchOpenAccessPublished:23January2012ThevalueofCDX2andcytokeratins7and20expressionindifferentiatingcolorectaladenocarcinomasfromextraintestinalgastrointestinaladenocarcinomas:cytokeratin7-/20+phenotypeismorespecificthanCDX2antibodyReyhanBayrak1,HacerHaltas1&SibelYenidunya1 DiagnosticPathologyvolume 7,Article number: 9(2012)Citethisarticle59kAccesses92Citations2AltmetricMetricsdetailsAbstractBackground/ObjectiveMetastaticadenocarcinomafromanunknownprimarysiteisacommonclinicalproblem.Determiningthecytokeratin(CK)7/CK20patternoftumorsisoneofthemosthelpfulproceduresforthispurposesincetheCK7-/CK20+patternistypicalofcolorectaladenocarcinomas.CDX2,acriticalnucleartranscriptionfactorforintestinaldevelopment,isexpressedinintestinalepitheliumandadenocarcinomas.Inthepresentstudy,wecomparedthesensitivityandspecificityofCDX2expressionandtheCK7-/CK20+phenotypeindifferentiatingcolorectaladenocarcinomasfrompancreaticandgastricadenocarcinomas.MethodsCK7/CK20stainingpatternandCDX2expressionwereevaluatedin118casesofcolorectal,59casesofgastric,and32casesofpancreaticadenocarcinomas.Thesensitivity,specificity,andpositiveandnegativepredictivevaluesoftheCK7-/CK20+phenotypeandofCDX2expressionwereanalyzed.ResultsTheCK7-/CK20+immunophenotypewasexpressedby75of118(64%)colorectaland3of59(5%)gastrictumorsandwasnotobservedinanypancreaticadenocarcinomas.TheCK7+/CK20+immunophenotypewasexpressedin24/118(20%)ofcolon,28/59(48%)ofgastricand7/32(22%)ofpancreaticadenocarcinomas.TheCK7+/CK20-expressionpatternwasobservedinonly2%(2of118)ofcolorectalcarcinomas.CDX2wasexpressedin114of118(97%)colorectal,36of59(61%)gastric,and5of32(16%)pancreaticadenocarcinomas.TherewasnosignificantassociationbetweenCDX2expressionandtumordifferentiationincolorectalcarcinomas.Ingastriccarcinomas,CDX2expressionwasmorecomm

CK7+ / CK20+ in carcinomas of bile duct (extrahepatic / gallbladder, often, Pathol Res Pract 2003;199:65), lung-mucinous bronchioloalveolar ...AuthorsBlogBoardReviewCommentContactUsNewslettersStatisticsTestimonialsSeeElsevier'snewvideoabouttheirClinicReviewArticlesonourhomepageorclickhere.JobsFellowshipsConferences/WebinarsBooksCMECasesAdvertiseGrantsMedicalNewsLibrariesRocheCompanionDiagnosticLibraryRocheNTRKIHCDiagnosticLibraryCOVID-19LibraryPandemicreliefmusicawardHome>Stains&molecularmarkers>Cytokeratin20(CK20,K20)Stains&molecularmarkersCytokeratin20(CK20,K20)Author: NatPernick,M.D.TopicCompleted:1July2013Minorchanges:19October2020Copyright:2003-2021,PathologyOutlines.com,Inc.PubMedSearch:CK20[title]Pageviewsin2020:17,186Pageviewsin2021todate:6,192TableofContentsDefinition/general|Usesbypathologists|Microscopic(histologic)images|Positivestaining-normal|Positivestaining-notmalignant|Positivestaining-malignant|NegativestainingCitethispage:HamiltonK,PernickN.Cytokeratin20(CK20,K20).PathologyOutlines.comwebsite.https://www.pathologyoutlines.com/topic/stainsck20.html.AccessedApril21st,2021.Definition/generalEpithelialmarker(MW46kDa)withrestrictedexpressioncomparedtoCK7(OMIM#608218)UsesbypathologistsGeneralpatterns(specificityvaries)CK7+/CK20+incarcinomasofbileduct(extrahepatic/gallbladder,often,PatholResPract2003;199:65),lung-mucinousbronchioloalveolar(AmJClinPathol2004;122:421),pancreas(Cancer2006;106:693,butseeArchPatholLabMed2000;124:1196)Urothelium(often,ArchPatholLabMed2001;125:921,HumPathol2002;33:1136)Alsoprimarymucinoustumorsofovary(74%),upperGItract(78%)andendocervix(88%,AmJSurgPathol2006;30:1130)CK7+/CK20-incarcinomasofbileduct(intrahepatic,PatholResPract2003;199:65),breast(AnnDiagnPathol1999;3:350),endocervicalandendometrialadenocarcinoma(PatholResPract2003;199:65),esophagus(distal,AmJSurgPathol2002;26:1213),lung(notmucinousbronchioloalveolar,BMCCancer2006;6:31),salivarygland(PatholInt2005;55:386),thyroid(ApplImmunohistochemMolMorphol2000;8:189)Alsomesothe

GroupCAP_logo_rgb[1]UserSkiptoMainContentAccesse-LABSolutionsSuiteDownArrowELSSMainPageOrganizationProfileResultFormDataEntryEvaluationReportsChecklistsCompetencyAssessmentProgramJointheCAPShoppingCartShopLoginCAPLogoMemberResourcesDownArrowJoin/RenewResidentsMedicalStudentsNewinPracticeHouseofDelegatesPracticeManagementPathologyCareersCouncilsandCommitteesAdvocacyDownArrowPaymentsforPathologyServicesLobbyingandPoliticalActionQualityPaymentProgramforPathologistsPathologistsQualityRegistryLaboratoryOversightandRegulationLatestNewsandPracticeDataLaboratoryImprovementDownArrowAccreditationProficiencyTestingInternationalLaboratoriesCatalogandOrderingInformationNewsandUpdatesLearningDownArrowPathologistsLearningProgramsLaboratoryProfessionalsLearningProgramsProtocolsandGuidelinesDownArrowCancerReportingToolsCancerProtocolsUpcomingCAPGuidelinesCurrentCAPGuidelinesPublicationsDownArrowCAPTodayArchivesofPathology&LaboratoryMedicineCAPPressPublicationsToggleNavigationMenuCAPLogoUserLoginLoginSearchMemberResourcesDownArrowJoin/RenewResidentsMedicalStudentsNewinPracticeHouseofDelegatesPracticeManagementPathologyCareersCouncilsandCommitteesAdvocacyDownArrowPaymentsforPathologyServicesLobbyingandPoliticalActionQualityPaymentProgramforPathologistsPathologistsQualityRegistryLaboratoryOversightandRegulationLatestNewsandPracticeDataLaboratoryImprovementDownArrowAccreditationProficiencyTestingInternationalLaboratoriesCatalogandOrderingInformationNewsandUpdatesLearningDownArrowPathologistsLearningProgramsLaboratoryProfessionalsLearningProgramsProtocolsandGuidelinesDownArrowCancerReportingToolsCancerProtocolsUpcomingCAPGuidelinesCurrentCAPGuidelinesPublicationsDownArrowCAPTodayArchivesofPathology&LaboratoryMedicineCAPPressPublicationsAccesse-LABSolutionsSuiteDownArrowELSSMainPageOrganizationProfileResultFormDataEntryEvaluationReportsChecklistsCompetencyAssessmentProgramJointheCAPShoppingCartShopUpdateMyProfileAccessMyCommitteesViewMyOrderHistoryAccessMyTranscriptChangePasswordLogoutHom

a through d, The use of CK7 and CK20 to further classify CK+ and S100 ... Neoplasms likely to be CK+/S100−/LCA−/vimentin+ with an outline for ... an indispensable ancillary study and is crucial in oncologic pathology.SkiptoMainContentSearchsearchinputSearchinputautosuggestSearchUserToolsRegisterSignInToggleMenuMenuHomeIssuesCurrentIssueAvailableIssuesEarlyOnlineReleaseWeb-OnlyArticleIndexSubmitaManuscriptEditorialBoardSubscribeInstructionsforAuthorsInstructionsforAuthorsAuthorshipFormSubmitManuscriptsAdvertisingJobsSkipNavDestinationArticleNavigationClosemobilesearchnavigationArticlenavigationVolume138,Issue121December2014PreviousArticleNextArticleHOWTOAPPROACHUNDIFFERENTIATEDNEOPLASMS/TUMORSOFUNCERTAINORIGINRECOMMENDEDDIAGNOSTICIMMUNOHISTOCHEMICALPANELSDIAGNOSTICIMMUNOHISTOCHEMICALPANELSBASEDONHISTOMORPHOLOGYMOLECULARPROFILINGFORIDENTIFICATIONOFATUMOROFUNCERTAINORIGINCONCLUSIONSReferencesArticleNavigationother|December012014ImmunohistochemistryinUndifferentiatedNeoplasm/TumorofUncertainOriginFanLin,MD,PhD;FanLin,MD,PhDFromtheDepartmentofLaboratoryMedicine,GeisingerMedicalCenter,Danville,Pennsylvania.Searchforotherworksbythisauthoron:ThisSitePubMedGoogleScholarHaiyanLiu,MDHaiyanLiu,MDFromtheDepartmentofLaboratoryMedicine,GeisingerMedicalCenter,Danville,Pennsylvania.Searchforotherworksbythisauthoron:ThisSitePubMedGoogleScholarArchPatholLabMed(2014)138(12):1583–1610.https://doi.org/10.5858/arpa.2014-0061-RASplit-ScreenViewsIconViewsArticlecontentsFigures&tablesVideoAudioSupplementaryDataPDFLinkPDFShareIconShareFacebookTwitterLinkedInEmailGuestAccessToolsIconToolsGetPermissionsCiteIconCiteSearchSiteCitationFanLin,HaiyanLiu;ImmunohistochemistryinUndifferentiatedNeoplasm/TumorofUncertainOrigin.ArchPatholLabMed1December2014;138(12):1583–1610.doi:https://doi.org/10.5858/arpa.2014-0061-RADownloadcitationfile:Ris(Zotero)ReferenceManagerEasyBibBookendsMendeleyPapersEndNoteRefWorksBibTextoolbarsearchSearchsearchinputSearchinputautosuggestSearchContextImmunohistochemistryhasbec